Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus

被引:57
作者
Compeyrot-Lacassagne, Sandrine [1 ]
Tyrrell, Pascal N. [1 ]
Atenafu, Eshetu [1 ]
Doria, Andrea S. [1 ]
Stephens, Derek [1 ]
Gilday, David [1 ]
Silverman, Earl D. [1 ]
机构
[1] Univ Toronto, Div Rheumatol, Hosp Sick Children, Toronto, ON M5G 1X8, Canada
来源
ARTHRITIS AND RHEUMATISM | 2007年 / 56卷 / 06期
关键词
D O I
10.1002/art.22691
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objective. Studies of adults with systemic lupus erythematosus (SLE) have frequently demonstrated the presence of decreased bone mineral density (BMD). However, there have been few investigations in pediatric patients to date. This study was undertaken to determine the prevalence of low BMD in patients with juvenile SLE and to identify associated risk factors. Methods. We studied 64 consecutive patients with juvenile SLE in whom routine dual x-ray absorptiometry (DXA) scanning was performed. Lumbar spine osteopenia was defined as a BMD Z score of < -1 and >=-2.5, and osteoporosis as a BMD Z score of < - 2.5. Decreased hip BMD was defined as a value of <80%. Data on disease activity, quality of life, disease-related damage, sex, ethnicity, body mass index, age at diagnosis, age at DXA, medication use and duration, clinical features, and puberty status were collected at the time of DXA. Results. Lumbar spine osteopenia was seen in 24 patients (37.5%) and osteoporosis in 13 (20.3%). Decreased hip BMD was present in 12 patients (18.8%). By univariate analysis, osteopenia was significantly correlated with age, disease duration, duration of corticosteroid use, cumulative corticosteroid dose, azathioprine use, cyclophosphamide use, lupus nephritis, and damage. Two additional variables, mycophenolate mofetil use and class III-IV nephritis, were associated with osteoporosis. Abnormal hip BMD was associated with disease duration, duration of corticosteroid use, and cumulative corticosteroid dose. By multivariate analysis, only disease duration remained in the model for osteoporosis and abnormal hip BMD, while cumulative corticosteroid dose was the variable associated with osteopenia. Conclusion. These results indicate that osteopenia and osteoporosis are common in juvenile SLE and are associated more closely with increased disease duration than with cumulative corticosteroid dose.
引用
收藏
页码:1966 / 1973
页数:8
相关论文
共 55 条
[1]
Alsufyani KA, 2005, J RHEUMATOL, V32, P729
[2]
[Anonymous], 1991, Osteoporos Int, V1, P114
[3]
Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage [J].
Becker, A ;
Fischer, R ;
Scherbaum, WA ;
Schneider, M .
LUPUS, 2001, 10 (11) :809-814
[4]
Bone mineral density in women with systemic lupus erythematosus [J].
Bhattoa, HP ;
Bettembuk, P ;
Balogh, A ;
Szegedi, G ;
Kiss, E .
CLINICAL RHEUMATOLOGY, 2002, 21 (02) :135-141
[5]
Bhudhikanok GS, 1996, J BONE MINER RES, V11, P1545
[6]
DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[7]
Moderate exercise during growth in prepubertal boys: Changes in bone mass, size, volumetric density, and bone strength: A controlled prospective study [J].
Bradney, M ;
Pearce, G ;
Naughton, G ;
Sullivan, C ;
Bass, S ;
Beck, T ;
Carlson, J ;
Seeman, E .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (12) :1814-1821
[8]
European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus [J].
Brunner, HI ;
Silverman, ED ;
Bombardier, C ;
Feldman, BM .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2003, 49 (03) :335-341
[9]
Risk factors for damage in childhood-onset systemic lupus erythematosus - Cumulative disease activity and medication use predict disease damage [J].
Brunner, HI ;
Silverman, ED ;
To, T ;
Bombardier, C ;
Feldman, BM .
ARTHRITIS AND RHEUMATISM, 2002, 46 (02) :436-444
[10]
Brunner HI, 1999, ARTHRITIS RHEUM-US, V42, P1354, DOI 10.1002/1529-0131(199907)42:7<1354::AID-ANR8>3.0.CO